Norman Johanna L, Holmes Whitney L, Bell William A, Finks Shannon W
Le Bonheur Children's Hospital, Memphis, TN, USA.
J Pharm Pract. 2013 Aug;26(4):382-8. doi: 10.1177/0897190012465990. Epub 2012 Nov 25.
Angiotensin-converting enzyme inhibitors (ACE-Is) are the primary medication class implicated in drug-associated angioedema. Angioedema is most common early in ACE-I therapy, yet episodes can occur late in therapy and have been reported even as late as 10 years after single treatment initiation. We present a case of a 65-year-old African American woman who experienced 2 episodes of angioedema, with the second being life threatening after receiving several concomitant agents known to cause angioedema, most notably lisinopril for 11 years.
血管紧张素转换酶抑制剂(ACE-Is)是与药物相关的血管性水肿相关的主要药物类别。血管性水肿在ACE-I治疗早期最为常见,但发作也可能发生在治疗后期,甚至有报道称在单次开始治疗后长达10年仍会出现。我们报告了一例65岁的非裔美国女性病例,她经历了2次血管性水肿发作,第二次在接受了几种已知可导致血管性水肿的伴随药物后危及生命,最显著的是服用赖诺普利11年。